- Email: [email protected]
50μg Diskus® versus montelukast in patients previously receiving short-acting beta2-agonists
Abstracts S117
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2
Asthma Control With Fluticasone Propionate/Salmeterol 100/50µg Diskus® Versus Montelukast in Patients Previously Receiving Short-Acting Beta2-Agonists W. Calhoun1, L. Sutton2, A. Emmett2, P. Dorinsky2; 1Asthma, Allergy and Airway Research Center, University of Pittsburgh, Pittsburgh, PA, 2GlaxoSmithKline, Research Triangle Park, NC. RATIONALE: According to asthma guidelines, patients with persistent asthma can be classified as mild, moderate or severe based upon lung function, albuterol use and symptoms. Although asthma is a variable and unpredictable disease, few studies have used guideline classification to evaluate asthma control over time in response to treatment. METHODS: The analysis was based on patients (n=855) previously receiving short-acting beta2-agonists alone from two completed 12-week trials in which patients received fluticasone/salmeterol 100/50µg (FSC) BID or montelukast 10mg QD. Baseline values included AM PEF=7576% predicted; asthma symptoms=6.5-6.6 days/wk and albuterol use=6.4 days/wk. Asthma severity classification was based upon NIH criteria. RESULTS: With respect to AM PEF %predicted, FSC patients were classified as intermittent/mild, moderate or severe on 72%, 25% and 3% of weeks, compared with 50%, 38%, and 12% for montelukast. By week 3, >70% of FSC patients were classified as intermittent/mild based on AMPEF %predicted and they remained there until Week 12 compared with only 50% of montelukast recipients. FSC recipients spent 42%, 28% and 30% of weeks as intermittent, mild or moderate/severe based upon asthma symptoms, compared with 19%, 31% and 49% for montelukast. FSC patients spent 52%, 26% and 22% of weeks as intermittent, mild or moderate/severe based upon albuterol use compared with 27%, 30% and 44% for montelukast. Based upon AMPEF, 28% of patients receiving FSC changed severity categories >10 times compared with 46% of montelukast patients. CONCLUSIONS: This analysis clearly demonstrates that sustained asthma control was achieved more rapidly and in more patients receiving FSC compared with montelukast. (SAS40020/40021) Funding: GlaxoSmithKline
SUNDAY
366
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2
Asthma Control With Fluticasone Propionate/Salmeterol 100/50µg Diskus® Versus Montelukast in Patients Previously Receiving Short-Acting Beta2-Agonists W. Calhoun1, L. Sutton2, A. Emmett2, P. Dorinsky2; 1Asthma, Allergy and Airway Research Center, University of Pittsburgh, Pittsburgh, PA, 2GlaxoSmithKline, Research Triangle Park, NC. RATIONALE: According to asthma guidelines, patients with persistent asthma can be classified as mild, moderate or severe based upon lung function, albuterol use and symptoms. Although asthma is a variable and unpredictable disease, few studies have used guideline classification to evaluate asthma control over time in response to treatment. METHODS: The analysis was based on patients (n=855) previously receiving short-acting beta2-agonists alone from two completed 12-week trials in which patients received fluticasone/salmeterol 100/50µg (FSC) BID or montelukast 10mg QD. Baseline values included AM PEF=7576% predicted; asthma symptoms=6.5-6.6 days/wk and albuterol use=6.4 days/wk. Asthma severity classification was based upon NIH criteria. RESULTS: With respect to AM PEF %predicted, FSC patients were classified as intermittent/mild, moderate or severe on 72%, 25% and 3% of weeks, compared with 50%, 38%, and 12% for montelukast. By week 3, >70% of FSC patients were classified as intermittent/mild based on AMPEF %predicted and they remained there until Week 12 compared with only 50% of montelukast recipients. FSC recipients spent 42%, 28% and 30% of weeks as intermittent, mild or moderate/severe based upon asthma symptoms, compared with 19%, 31% and 49% for montelukast. FSC patients spent 52%, 26% and 22% of weeks as intermittent, mild or moderate/severe based upon albuterol use compared with 27%, 30% and 44% for montelukast. Based upon AMPEF, 28% of patients receiving FSC changed severity categories >10 times compared with 46% of montelukast patients. CONCLUSIONS: This analysis clearly demonstrates that sustained asthma control was achieved more rapidly and in more patients receiving FSC compared with montelukast. (SAS40020/40021) Funding: GlaxoSmithKline
SUNDAY
366